High-dose twice daily thoracic radiotherapy in limited disease small-cell lung cancer

Bookmark and Share
Published: 15 Jun 2020
Views: 102
Prof Bjørn Henning Grønberg - Trondheim University Hospital, Trondheim, Norway

Prof Bjørn Henning Grønberg speaks to ecancer about the results he was presenting at the ASCO 2020 Virtual meeting on a randomised phase II trial comparing the efficacy of standard-dose with high-dose twice-daily thoracic radiotherapy in limited disease small-cell lung cancer.

He explains the trial aimed to see if higher dose thoracic radiotherapy would be tolerable and lead to improved survival.

Prof Grønberg reports that, to their surprise, the higher dose was well tolerated and shows a significant improvement in 2-year survival at this point in the study. He discusses what can be expected from further results and what the impact on clinical care might be in the foreseeable future.